862073-85-6Relevant academic research and scientific papers
Neoclerodane diterpenes as a novel scaffold for μ opioid receptor ligands
Harding, Wayne W.,Tidgewell, Kevin,Byrd, Nathan,Cobb, Howard,Dersch, Christina M.,Butelman, Eduardo R.,Rothman, Richard B.,Prisinzano, Thomas E.
, p. 4765 - 4771 (2005)
Structural modification of salvinorin A, the active component of Salvia divinorum, has resulted in the synthesis of novel neoclerodane diterpenes with opioid receptor affinity and activity. We report in this study a nonnitrogenous neoclerodane diterpene w
Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues
Lee, David Y.W.,Karnati, Vishnu V.R.,He, Minsheng,Liu-Chen, Lee-Yuan,Kondaveti, Leelakrishna,Ma, Zhongze,Wang, Yulin,Chen, Yong,Beguin, Cecile,Carlezon Jr., William A.,Cohen, Bruce
, p. 3744 - 3747 (2005)
Salvinorin A is the most potent naturally occurring opioid agonist yet discovered with high selectivity and affinity for κ-opioid receptor. To explore its structure and activity relationships, a series of salvinorin A derivatives modified at the C(2) position were prepared and studied. These salvinorin A derivatives were screened for binding and functional activities at the human κ-opioid receptor. Compound 4, containing a methoxymethyl group at the 2-position, was a full κ-agonist with an EC50 value at 0.6 nM, which is about 7 times more potent than salvinorin A.
Opioid receptor ligands and methods for their preparation
-
Page/Page column 11; Figure 2, (2008/06/13)
The invention provides novel compounds of formula I: that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by a
Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2)
Beguin, Cecile,Richards, Michele R.,Wang, Yulin,Chen, Yong,Liu-Chen, Lee-Yuan,Ma, Zhongze,Lee, David Y. W.,Carlezon Jr., William A.,Cohen, Bruce M.
, p. 2761 - 2765 (2007/10/03)
Salvinorin A is the only known non-nitrogenous and specific κ-opioid agonist. A series of salvinorin A derivatives were prepared and tested for in vitro activity at the κ-opioid receptor. Unsubstituted carbamate 9 was a potent κ-agonist (EC50 = 6.2 nM) and should be more stable than salvinorin A toward metabolic transformations. Compound 10, containing an N-methyl carbamate at C(2), showed partial agonist activity with 81% efficacy when compared with the full agonist U50,488H. No antagonist ligands were observed.
